Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caris Life Sciences Inc (CAI)

Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,044,011
  • Shares Outstanding, K 282,147
  • Annual Sales, $ 294,010 K
  • Annual Income, $ 27,730 K
  • EBIT $ -113 M
  • EBITDA $ -113 M
  • 60-Month Beta N/A
  • Price/Sales 12.39
  • Price/Cash Flow N/A
  • Price/Book 16.76

Options Overview Details

View History
  • Implied Volatility 90.66% (+7.34%)
  • Historical Volatility 40.43%
  • IV Percentile 87%
  • IV Rank 76.26%
  • IV High 98.49% on 12/09/25
  • IV Low 65.51% on 07/18/25
  • Expected Move (DTE 4) 3.36 (12.43%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 8
  • Volume Avg (30-Day) 454
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 9,796
  • Open Int (30-Day) 11,275
  • Expected Range 23.65 to 30.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate 0.00
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.52 +5.84%
on 12/15/25
29.32 -7.88%
on 01/07/26
+0.25 (+0.93%)
since 12/12/25
3-Month
22.86 +18.15%
on 11/07/25
33.65 -19.73%
on 10/16/25
-3.47 (-11.38%)
since 10/10/25

Most Recent Stories

More News
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results

Full year revenue growth of approximately 94% driven by strong performance  in molecular profiling services

CAI : 26.02 (-8.73%)
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect

IRVING, Texas , Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 26.02 (-8.73%)
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

IRVING, Texas , Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences ®  (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 26.02 (-8.73%)
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute

IRVING, Texas , Dec. 19, 2025 /PRNewswire/ --  Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 26.02 (-8.73%)
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need

IRVING, Texas , Dec. 16, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 26.02 (-8.73%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.140 (+3.70%)
CCLD : 2.96 (-2.95%)
ABSI : 3.30 (-1.20%)
LNAI : 0.9100 (-5.21%)
CAI : 26.02 (-8.73%)
VPTDF : 0.0985 (+4.45%)
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

IRVING, Texas , Dec. 4, 2025 /PRNewswire/ --  Caris Life Sciences ®  (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 26.02 (-8.73%)
The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute

IRVING, Texas , Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...

CAI : 26.02 (-8.73%)
Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class

IRVING, Texas , Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 26.02 (-8.73%)
Caris Life Sciences to Attend Q4 2025 Investor Conferences

IRVING, Texas , Nov. 17, 2025 /PRNewswire/ --  Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced...

CAI : 26.02 (-8.73%)

Business Summary

Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving,...

See More

Key Turning Points

3rd Resistance Point 30.03
2nd Resistance Point 29.36
1st Resistance Point 28.93
Last Price 26.02
1st Support Level 27.83
2nd Support Level 27.16
3rd Support Level 26.73

See More

52-Week High 42.50
Fibonacci 61.8% 35.00
Fibonacci 50% 32.68
Fibonacci 38.2% 30.36
Last Price 26.02
52-Week Low 22.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar